| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5795864 | TERSERA | Stable omega conopetide formulations |
Jun, 2015
(8 years ago) | |
| US5364842 | TERSERA | Method of producing analgesia |
Dec, 2016
(7 years ago) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(5 months from now) | |
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(5 months from now) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(5 months from now) | |
Prialt is owned by Tersera.
Prialt contains Ziconotide Acetate.
Prialt has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Prialt are:
- US5795864
- US5364842
Prialt was authorised for market use on 28 December, 2004.
Prialt is available in injectable;intrathecal dosage forms.
Prialt can be used as treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine, analgesia, treatment of pain.
The generics of Prialt are possible to be released after 01 October, 2024.
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Analgesia; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Treatment of pain
Dosage: INJECTABLE;INTRATHECAL
PRIALT family patents
